| abstract |
The present disclosure provides stimulants of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or administration comprising the same, alone or in combination with one or more additional agents, for the treatment of a variety of CNS disorders. form, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO) or cyclic guanosine 3',5'-monophosphate (cGMP) or both, or upregulation of the NO pathway desirable. |